URGNHIGH SIGNALFINANCIAL10-K

URGN experienced a dramatic revenue collapse while burning through cash at an accelerated rate, raising serious concerns about the commercial viability of its approved products.

The company's revenue decline to just $1.1M signals major commercial challenges with its two approved oncology products, Jelmyto and Zusduri, despite management emphasizing their dependence on these drugs' successful commercialization. The substantial increase in cash burn combined with a $61M decline in cash reserves creates urgent funding pressures for this specialty pharmaceutical company.

Comparing 2026-03-02 vs 2025-03-10View on EDGAR →
FINANCIAL ANALYSIS

URGN's financial position deteriorated markedly, with revenue collapsing from $8.2M to $1.1M while operating losses widened to $124.9M. The company burned through cash substantially faster, with operating cash flow declining meaningfully to -$162.4M, while cash reserves dropped over one-third to $110.7M. Despite the revenue challenges, both inventory and accounts receivable grew notably, suggesting either pipeline preparation or collection difficulties that warrant close monitoring.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
-86.2%
$8.2M→$1.1M

Revenue declined 86.2% — significant demand weakness or market share loss warrants investigation.

Inventory
Balance Sheet
+78.4%
$9.2M→$16.5M

Inventory surged 78.4% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Operating Cash Flow
Cash Flow
-67.9%
-$96.8M→-$162.4M

Operating cash flow fell 67.9% — earnings quality concerns; investigate working capital changes and non-cash items.

Accounts Receivable
Balance Sheet
+62.9%
$20.3M→$33.1M

Receivables surged 62.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Cash & Equivalents
Balance Sheet
-35.6%
$172.0M→$110.7M

Cash declined 35.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-32.6%
$276.1M→$186.0M

Current assets declined 32.6% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-29.8%
$285.7M→$200.5M

Total assets contracted 29.8% — asset sales, write-downs, or balance sheet optimization underway.

Operating Income
P&L
-29%
-$96.8M→-$124.9M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

SG&A Expense
P&L
+28%
$121.2M→$155.1M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Net Income
P&L
-21%
-$126.9M→-$153.5M

Net income declined 21% — review whether driven by operations, interest costs, or non-recurring items.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-03-10
ADDED
Other expenses primarily consist of insurance, sponsorship, grants, other fees and taxes.
$0.2 million of raw materials are included within other non-current assets on the condensed consolidated balance sheets at December 31, 2024.
Such value excludes ordinary shares held by executive officers, directors and certain entities affiliated with directors as of June 30, 2025.
As of February 24, 2026, there were 48,682,280 of the registrant s ordinary shares outstanding.
UroGen, RTGel, Jelmyto and Zusduri are trademarks of ours that we use in this Annual Report on Form 10-K (this "Annual Report").
We are highly dependent on the successful commercialization of our approved products, Jelmyto and Zusduri .
We currently contract with third-party subcontractors and single-source suppliers for certain raw materials, compounds and components necessary to produce Jelmyto and Zusduri for commercial use, and to produce and administer UGN-103, UGN-104 and UGN-501 for nonclinical studies and clinical trials, and expect to continue to do so to support commercial scale production of UGN-103, UGN-104 and UGN-501, if approved; or for any approved products that include UGN-501.
This increases the risk that we will not have sufficient quantities of Jelmyto , Zusduri , UGN-103, UGN-104 or UGN-501, or be able to obtain such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
We have incurred significant losses and negative cash flows since our inception, and we anticipate that we will continue to incur losses and negative cash flows as we execute on our strategy and may not generate positive or sufficient cash flows from operations in the future, which may have an adverse impact on our working capital, total assets, stockholders equity and our ability to service our indebtedness and commitments.
REMOVED
$0.2 million and $1.7 million of raw materials are included within other non-current assets on the consolidated balance sheets at December 31, 2024 and December 31, 2023, respectively.
The loss per share, both basic and diluted, for the first, second, and third quarters of 2024 was revised to record an immaterial correction to the amounts originally reported in the March 31, 2024 Form 10-Q filed on May 13, 2024, June 30, 2024 Form 10-Q filed on August 13, 2024, and September 30, 2024 Form 10-Q filed on November 6, 2024, by incorporating the 3,679,400 shares of pre-funded warrants outstanding as of each respective reporting period, which were not included in the previous calculations and are now reflected in the weighted average shares outstanding.
In the course of preparing the 2022 tax returns, adjustments were made for certain nondeductible amounts, reducing net operating loss carryforward and reflected as a change in valuation allowance of approximately $8.9 million in 2023.
$6.5 million and $3.0 million of the Amounts paid and payable are included as current portion of the prepaid forward obligation within other current liabilities on the consolidated balance sheets as of December 31, 2024 and December 31, 2023, respectively.
Such value excludes ordinary shares held by executive officers, directors and certain entities affiliated with directors as of June 28, 2024.
As of March 3, 2025, there were 46,094,352 of the registrant s ordinary shares outstanding.
UroGen RTGel and Jelmyto are trademarks of ours that we use in this Annual Report on Form 10-K (this "Annual Report").
We are highly dependent on the successful commercialization of our only approved product, Jelmyto .
In addition to Jelmyto , we are dependent on the success of our lead product candidate, UGN-102, and our other product candidates, including obtaining regulatory approval to market our product candidates in the United States.
The data from our pivotal Phase 3 ENVISION trial and supporting ATLAS and OPTIMA II trials may be insufficient to support regulatory approval of UGN-102.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →